Literature DB >> 20661557

Molecular imaging in cancer treatment.

Mark H Michalski1, Xiaoyuan Chen.   

Abstract

The success of cancer therapy can be difficult to predict, as its efficacy is often predicated upon characteristics of the cancer, treatment, and individual that are not fully understood or are difficult to ascertain. Monitoring the response of disease to treatment is therefore essential and has traditionally been characterized by changes in tumor volume. However, in many instances, this singular measure is insufficient for predicting treatment effects on patient survival. Molecular imaging allows repeated in vivo measurement of many critical molecular features of neoplasm, such as metabolism, proliferation, angiogenesis, hypoxia, and apoptosis, which can be employed for monitoring therapeutic response. In this review, we examine the current methods for evaluating response to treatment and provide an overview of emerging PET molecular imaging methods that will help guide future cancer therapies.

Entities:  

Mesh:

Year:  2010        PMID: 20661557      PMCID: PMC3022114          DOI: 10.1007/s00259-010-1569-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  203 in total

1.  Curvature-dependent recognition of ethanolamine phospholipids by duramycin and cinnamycin.

Authors:  Kunihiko Iwamoto; Tomohiro Hayakawa; Motohide Murate; Asami Makino; Kazuki Ito; Tetsuro Fujisawa; Toshihide Kobayashi
Journal:  Biophys J       Date:  2007-05-04       Impact factor: 4.033

2.  Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.

Authors:  James P B O'Connor; Gordon C Jayson; Alan Jackson; Dana Ghiorghiu; Bernadette M Carrington; Chris J Rose; Samantha J Mills; Ric Swindell; Caleb Roberts; Claire L Mitchell; Geoffrey J M Parker
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

3.  Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.

Authors:  Gerald Reischl; Donna S Dorow; Carleen Cullinane; Andrew Katsifis; Peter Roselt; David Binns; Rodney J Hicks
Journal:  J Pharm Pharm Sci       Date:  2007       Impact factor: 2.327

4.  Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT).

Authors:  Carla F M Molthoff; Bianca M Klabbers; Johannes Berkhof; Jasper T Felten; Marcelle van Gelder; Albert D Windhorst; Ben J Slotman; Adriaan A Lammertsma
Journal:  Mol Imaging Biol       Date:  2007 Nov-Dec       Impact factor: 3.488

5.  Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.

Authors:  M Souvatzoglou; A L Grosu; B Röper; B J Krause; R Beck; G Reischl; M Picchio; H-J Machulla; H-J Wester; M Piert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-20       Impact factor: 9.236

6.  99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome.

Authors:  Marina S Kartachova; Renato A Valdés Olmos; Rick L M Haas; Frank J P Hoebers; Marcel van Herk; Marcel Verheij
Journal:  Nucl Med Commun       Date:  2008-01       Impact factor: 1.690

7.  Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.

Authors:  Sadek A Nehmeh; Nancy Y Lee; Heiko Schröder; Olivia Squire; Pat B Zanzonico; Yusuf E Erdi; Carlo Greco; Gig Mageras; Hai S Pham; Steve M Larson; Clifton C Ling; John L Humm
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-01-01       Impact factor: 7.038

8.  Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT.

Authors:  Andreas K Buck; Clemens Kratochwil; Gerhard Glatting; Malik Juweid; Martin Bommer; Djurdja Tepsic; Andreas T J Vogg; Torsten Mattfeldt; Bernd Neumaier; Peter Möller; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-31       Impact factor: 9.236

9.  Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.

Authors:  Laura Kenny; R Charles Coombes; David M Vigushin; Adil Al-Nahhas; Sami Shousha; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-02       Impact factor: 9.236

10.  Regulated proteolytic processing of Tie1 modulates ligand responsiveness of the receptor-tyrosine kinase Tie2.

Authors:  Marie B Marron; Harprit Singh; Tariq A Tahir; Jais Kavumkal; Hak-Zoo Kim; Gou Young Koh; Nicholas P J Brindle
Journal:  J Biol Chem       Date:  2007-08-29       Impact factor: 5.157

View more
  31 in total

1.  Automated radiosynthesis of [(18)F]ML-10, a PET radiotracer dedicated to apoptosis imaging, on a TRACERLab FX-FN module.

Authors:  Franck Sobrio; Marie Médoc; Ludovic Martial; Jérôme Delamare; Louisa Barré
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

2.  Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment.

Authors:  Min Yang; Haokao Gao; Xilin Sun; Yongjun Yan; Qimeng Quan; Wendy Zhang; Khalid A Mohamedali; Michael G Rosenblum; Gang Niu; Xiaoyuan Chen
Journal:  Mol Pharm       Date:  2011-02-15       Impact factor: 4.939

Review 3.  The role of nuclear medicine in modern therapy of cancer.

Authors:  Gabriela Kramer-Marek; Jacek Capala
Journal:  Tumour Biol       Date:  2012-03-24

4.  Evaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties.

Authors:  Yang Zhou; Young-Seung Kim; Xin Lu; Shuang Liu
Journal:  Bioconjug Chem       Date:  2012-03-06       Impact factor: 4.774

5.  The age of reason for FDG PET image-derived indices.

Authors:  Dimitris Visvikis; Mathieu Hatt; Florent Tixier; Catherine Cheze Le Rest
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-12       Impact factor: 9.236

6.  Relationship Between Aerobic Fitness, the Serum IGF-1 Profiles of Healthy Young Adult African American Males, and Growth of Prostate Cancer Cells.

Authors:  Rajagopalan Sridhar; Vernon Bond; Jacquelyn Dunmore-Griffith; Valerie M Cousins; Renshu Zhang; Richard M Millis
Journal:  Am J Mens Health       Date:  2016-06-22

7.  PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)Labeled recombinant human His10-annexin V.

Authors:  Haidong Qin; Ming-Rong Zhang; Lin Xie; Yanjie Hou; Zichun Hua; Minjin Hu; Zizheng Wang; Feng Wang
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-12-15

8.  Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET.

Authors:  Ning Guo; Fan Zhang; Xiaomeng Zhang; Jinxia Guo; Lixin Lang; Dale O Kiesewetter; Gang Niu; Quanzheng Li; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

9.  Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo.

Authors:  Maria Cekanova; Md Jashim Uddin; Joseph W Bartges; Amanda Callens; Alfred M Legendre; Kusum Rathore; Laura Wright; Amanda Carter; Lawrence J Marnett
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-26

10.  Impact of a multiple mice holder on quantitation of high-throughput MicroPET imaging with and without Ct attenuation correction.

Authors:  Frezghi Habte; Gang Ren; Timothy C Doyle; Hongguang Liu; Zhen Cheng; David S Paik
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.